Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

REGN-7075

Generic Name: REGN-7075

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Recruiting

Posted: 2024/06/18

Sponsor:Regeneron Pharmaceut...

ID:NCT06465329

A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

Phase 1

Recruiting

Posted: 2020/11/12

Sponsor:Regeneron Pharmaceut...

ID:NCT04626635

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Regeneron Expands Biologic Manufacturing Capacity with $3 Billion FUJIFILM Partnership

a month ago

Regeneron Pharmaceuticals has announced a $3 billion manufacturing agreement with FUJIFILM Diosynth Biotechnologies in North Carolina, nearly doubling its U.S. large-scale manufacturing capacity for biologic medicines.

ASCO 2024 Highlights: Key Updates in Cancer Therapies

a year ago

Bristol Myers Squibb's Opdivo/Yervoy combo demonstrated superior overall survival in first-line unresectable hepatocellular carcinoma compared to Lenvima or Nexavar.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy